Trump announces high tariffs on generic drugs starting 2028

The level of the planned tariffs is unusual: 100 percent on the import value, and one year later even 200 percent. Industry experts consider such rates extreme and difficult to enforce in practice, as generics often operate on thin margins and prices could rise rapidly. As of now, this is merely an announcement; a formal order or specific legal act has not been documented in the available sources.

Critics within U.S. politics point out that higher import tariffs on generic drugs could burden the U.S. healthcare system in the long term, as health insurers and patients would bear the additional costs. Pharmaceutical associations, which have not been quoted thus far, have not yet made any public statements. International reactions from the key manufacturing countries are also still pending, according to the available reports.

Possible consequences for patients

Regardless, the question of supply security is a recurring issue in U.S. politics. While the Trump administration wants to strengthen the U.S. as a manufacturing location, healthcare experts argue that a global supply chain has thus far ensured stable availability. Whether the planned tariffs actually come into force will depend on further political developments and possible court disputes.

Every year, billions of dollars are spent on generic drugs in the United States. Even a comparatively small price increase could, according to analysts, affect Medicaid and Medicare expenditures. Costs for chronically ill people who rely permanently on affordable medications are also likely to rise.

The pharmaceutical industry is watching the developments closely. Manufacturers from India and China, which serve a large share of the global generic drug market, must prepare for possible new trade rules. It remains unclear whether exemptions are planned for individual active ingredients or whether the tariffs will be imposed across the board on all generic medications.

Reactions from the pharmaceutical industry

Trump had already announced in earlier statements his intention to hold the pharmaceutical industry more accountable. The planned tariff increase is part of a broader strategy that also includes tariffs on steel, aluminum, and semiconductors. Observers see the move as a signal to the industry to step up its investments in the United States.

If the tariffs take effect, the U.S. market for generic drugs is likely to be fundamentally restructured over the coming years. Until then, however, the announcement remains a political signal whose practical consequences cannot yet be foreseen. The Trump administration has not yet published a concrete timeline for implementing the order.